References
- Marchant J. When antibiotics turn toxic. Nature. 2018;555:431–433 .
- Tsai WC, Hsu CC, Chen CP, et al. Ciprofloxacin up-regulates tendon cells to express matrix metalloproteinase-2 with degradation of type I collagen. J Orthop Res. 2011;29:67–73.
- Reviglio VE, Hakim MA, Song JK, et al. Effect of topical fluoroquinolones on the expression of matrix metalloproteinases in the cornea. BMC Ophthalmol. 2003 Oct;6(3):10.
- Guzzardi DG, Teng G, Kang S, et al. Induction of human aortic myofibroblast-mediated extracellular matrix dysregulation: a potential mechanism of fluoroquinolone-associated aortopathy. J Thorac Cardiovasc Surg. 2019 Jan;157(1):109–119.e2. Epub 2018 Sep 21.
- Kaur K, Fayad R, Saxena A, et al. Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network. J Community Support Oncol. 2016;14(2):54–65.
- Bennett A, Qureshi ZP, Bennett CL. A novel genetic marker has been identified in patients with fluoroquinolone-associated neuropyschiatric toxicity: preliminary findings. Fed Pract. 2017; S30. (abstract).
- Schroeder MO. Could taking that antibiotic have serious long-term consequences? US News and World Report. 2018 Aug 30; [cited 2019 Feb 18]. Available from: https://www.msn.com/en-us/health/medical/could-taking-that-antibiotic-have-serious-long-term-consequences/ar-BBMEvqy
- FDA Pharmacovigilance Review. 2013 Apr 17; [cited 2019 Feb 18]. Available from: https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm467383.pdf
- Lee CC, Lee MT, Chen YS, et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med. 2015 Nov 1;175(11):1839–1847.
- Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open. 2015 Nov 18;5(11):e010077.
- Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018 Mar 8;360:k678.
- Howard DPJ, Banerjee A, Fairchild JF, et al. Age-specific incidence, risk factors and outcome of acute abdominal aortic aneurysms in a defined population. Br J Surg. 2015;102:907–915.
- Rao GA, Mann JR, Shoaibi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med. 2014;2014(12):121–127.
- Chou HW, Wang JL, Chang CH, et al. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and betalactam/beta-lactamase inhibitors: a taiwanese nationwide study. Clin Infect Dis. 2015;60:566–577.
- FDA Briefing Document - Joint Meeting of the Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. The benefits and risks of systemic fluoroquinolone antibacterial drugs for the treatment of Acute Bacterial Sinusitis (ABS), Acute Bacterial Exacerbation of Chronic Bronchitis in Patients Who Have Chronic Obstructive Pulmonary Disease (ABECB-COPD), and Uncomplicated Urinary Tract Infections (uUTI). 2015 Nov 5; [cited 2019 Jun 25]. Available from https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm467383.pdf
- Woodcock J. FDA. Partial approval and partial denial response from FDA to the Southern Network on Adverse Reactions (SONAR) regarding levaquin; [cited 2019 Feb 18]. Available from: https://www.regulations.gov/document?D=FDA-2014-P-1611-0005
- European Medicines Agency. Review of quinolone and fluoroquinolone-containing medicinal products; [cited 2019 Feb 18]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products
- Bennett CL for SONAR. Citizen petition from Southern Network on Adverse Reactions (SONAR) [for label change to include ‘possible FO-associated mitochondrial toxicity’]; [Updated 2014 Jun 18; posted Jul 17, 2014; cited 2015 Jul 28]. Available from: http://www.regulations.gov/#!documentDetail;D=FDA-2014-P-0856-0001
- Bennett CL for SONAR. Citizen petition from Southern Network on Adverse Reactions (SONAR) [for risk evaluation and mitigation strategy]; 2018 Jun 21.
- European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC): 9- 12. 2018 Jul 9–12; [cited 2019 Jun 25]. Available from: https://www.ema.europa.eu/en/events/pharmacovigilance-risk-assessment-committee-prac-9-12-july-2018
- European Commission Final Decision: Disabling and potentially permanent side effects lead to suspension or restrictions on use of FQs. Mar 2019 11; [cited 2018 Jun 21]. Available from: https://www.ema.europa.eu/en/documents/referral/quinolone-fluoroquinolone-article-31-referral-disabling-potentially-permanent-side-effects-lead_en.pdf
- Request by German medicine authority (BFArM) under Article 31 of Directive 2001/83/EC. Initiiated Feb 9, 2017. Timetable established Jul 12, 2018; [cited 2019 Jun 25]. Available from: https://www.ema.europa.eu/en/documents/referral/quinolone-fluoroquinolone-article-31-referral-timetable-procedure_en.pdf
- PRAC Recommendations on FQs by the European Union Pharmacovigialance Risk Assessment Committee. 2018 Oct 5; [cited 2018 Jun 21]. Available from: https://www.ema.europa.eu/en/documents/referral/quinolone-fluoroquinolone-article-31-referral-prac-recommends-restrictions-use_en.pdf
- FDA Drug Safety Communication. FDA reinforces safety information about serious low blood sugar side effects and mental health side effects with FQs; requires label changes. 2018 Jul 10; [cited 2019 Jun 21]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side
- Therapeutics Goods Administration. FQ antibiotics and risk of aortic aneurysm/dissection. 2019 Apr 12; [cited 2019 Jun 21]. Available from: https://www.tga.gov.au/publication-issue/fluoroquinolone-antibiotics-and-risk-aortic-aneurysmdissection
- Canada Health. Summary safety review: FQs- assessing the potential risk of persistent and disabling side effects. 2017 January 23; [cited 2019 Jun 21]. Available from: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/61900a-eng.php
- Health Care Professional Letter. FQs- risk of disabling and persistent serous adverse reactions including tendinopathy, peripheral neuropathy, and central nervous system disorders. 2017 Jan 23; [cited 2019 Jun 25]. Available from: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/61900a-eng.php
- Alberta Health Services. Antimicrobial stewardship backgrounder- FQs not a first line choice. Issue 16: June - November 2018; [cited 2019 Jun 21]. Available from: https://www.albertahealthservices.ca/assets/info/hp/as/if-hp-asb-2018-11-issue-16.pdf
- FDA Drug Safety Communication. FDA warns about increased risk of ruptures or tears in the aortal blood vessel with FQs antibiotics in certain patients. 2018 Dec 12; [cited 2019 Jun 21]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics
- Kommalapati A, Wallem S, Qureshi ZP, et al. Fluoroquinolone-associated suicide. Eur J Internal Med. 2018 Sep;55:e21-e22. doi: 10.1016/j.ejim.2018.07.012. Epub 2018 Jul 18.
- United States District Court, District of Minnesota. Description of MDL # 15-MD-2642; [cited 2019 Jun 22]. Available from: https://www.mnd.uscourts.gov/MDL-Fluoroquinolone/introduction.shtml
- United States District Court, District of Minnesota. Description of MDL #08-1943; [cited 2019 Jun 22]. Available from: https://www.mnd.uscourts.gov/MDL-Levaquin/introduction.shtml
- Moore TJ, Bennett CL. Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012 Nov;38(8):905–907. Epub 2012 Oct 21.
- FDA Adverse Events Reporting System Dashboard; [cited 2019 Sept 3]. Available from: https://fis.fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-0135608ddc13/sheet/7a47a261-d58b-4203-a8aa-6d3021737452/state/analysis
- Core Elements of Outpatient Antibiotic Stewardship. Centers for disease control and prevention; [cited 2019 Sept 3]. Available from: https://www.cdc.gov/antibiotic-use/core-elements/outpatient.html
- Core Elements of Hospital Antibiotic Stewardship Programs. Centers for disease control and prevention; [cited 2019 Sep 3]. Available from: https://www.cdc.gov/antibiotic-use/core-elements/hospital.html